Capmatinib
Overview
Capmatinib is a tyrosine kinase inhibitor targeting the MET receptor, indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. It works by blocking the MET signaling pathways, which are active in various cancers.
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Capmatinib expires 22 Jul 2035 and exclusivity 6 May 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Capmatinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.